Evidence map›Paper›PMID 38701426›Full record

ArticleBlood2024

Motive and opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements (an LLMPP study).

Laura K Hilton, Brett Collinge, Susana Ben-Neriah, Waleed Alduaij, Haya Shaalan, Andrew P Weng, Manuela Cruz, Graham W Slack, Pedro Farinha, Tomoko Miyata-Takata and 30 more

Abstract read
In one paragraph

Article in Blood, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

40 authors.

Laura K HiltonCentre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.ORCID 0000-0002-6413-6586
Brett CollingeCentre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.ORCID 0000-0002-5860-2798
Susana Ben-NeriahCentre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.
Waleed AlduaijCentre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.ORCID 0000-0002-2365-5371
Haya ShaalanDepartment of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada.
Andrew P WengTerry Fox Laboratory, BC Cancer Research Institute, Vancouver, BC, Canada.ORCID 0000-0001-7394-5425
Manuela CruzDepartment of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada.
Graham W SlackCentre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.
Pedro FarinhaCentre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.ORCID 0000-0001-9364-9391
Tomoko Miyata-TakataCentre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.
Merrill BoyleCentre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.ORCID 0000-0002-7618-0103
Barbara MeissnerCentre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.
James R CookDepartment of Clinical Pathology, Cleveland Clinic, Cleveland, OH.ORCID 0000-0003-0456-8085
Sarah L OndrejkaDepartment of Clinical Pathology, Cleveland Clinic, Cleveland, OH.ORCID 0000-0001-9431-2889
German OttDepartment of Clinical Pathology, Robert-Bosch-Krankenhaus and Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.
Andreas RosenwaldInstitute of Pathology, University of Wurzburg, Wurzburg, Germany.
Elias CampoHematopathology Section, Hospital Clinic of Barcelona, Institut d'Investigaciones Biomediques August Pi I Sunyer, University of Barcelona, Barcelona, Spain.ORCID 0000-0001-9850-9793
Catalina AmadorDepartment of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, FL.ORCID 0000-0003-0352-5526
Timothy C GreinerDepartment of Pathology, Microbiology and Immunology, University of Nebraska Medical Center, Omaha, NE.ORCID 0000-0003-1470-8328
Philipp W RaessDepartment of Pathology and Laboratory Medicine, Oregon Health & Science University, Portland, OR.
Joo Y SongDepartment of Pathology, City of Hope, Duarte, CA.
Giorgio InghiramiDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY.ORCID 0000-0001-5566-0864
Elaine S JaffeLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.ORCID 0000-0003-4632-0301
Dennis D WeisenburgerDepartment of Pathology, Microbiology and Immunology, University of Nebraska Medical Center, Omaha, NE.
Wing C ChanDepartment of Pathology, City of Hope, Duarte, CA.
Klaus BeiskeDepartment of Pathology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Kai FuDepartment of Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
Jan DelabieDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.ORCID 0000-0001-5023-0689
Stefania PittalugaLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.ORCID 0000-0001-7688-1439
Javeed IqbalDepartment of Pathology, Microbiology and Immunology, University of Nebraska Medical Center, Omaha, NE.
George WrightDivision of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Laurie H SehnCentre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.
Kerry J SavageCentre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.ORCID 0000-0002-5835-9863
Andrew J MungallCanada's Michael Smith Genome Sciences Centre, BC Cancer Research Institute, Vancouver, BC, Canada.ORCID 0000-0002-0905-2742
Andrew L FeldmanDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.ORCID 0000-0001-5009-4808
Louis M StaudtLymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Christian SteidlCentre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.ORCID 0000-0001-9842-9750
Lisa M RimszaDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ.
Ryan D MorinCentre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.ORCID 0000-0003-2932-7800
David W ScottCentre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.ORCID 0000-0002-0435-5947

Funding

Molecular diagnosis and outcome prediction in lymphomaZIABC011006 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI STAUDT, LOUIS · 2009 to 2025
$21.0M
Lymphoma Disease Discovery and DefintionZIASC000550 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI JAFFE, ELAINE · 2009 to 2025
$16.9M
Preclinical Models and Therapeutics CoreP01CA229100 · NCI · MAYO CLINIC ARIZONA · PI SCOTT, DAVID WILLIAM · 2018 to 2022
$10.2M
NCI NIH HHS P01 CA229100
6 · The paper itself

Abstract

abstractRearrangements that place the oncogenes MYC, BCL2, or BCL6 adjacent to superenhancers are common in mature B-cell lymphomas. Lymphomas with diffuse large B-cell lymphoma (DLBCL) or high-grade morphology with both MYC and BCL2 rearrangements are classified as high-grade B-cell lymphoma with MYC and BCL2 rearrangements ("double hit"; HGBCL-DH-BCL2) and are associated with aggressive disease and poor outcomes. Although it is established that MYC rearrangements involving immunoglobulin (IG) loci are associated with inferior outcomes relative to those involving other non-IG superenhancers, the frequency of and mechanisms driving IG vs non-IG MYC rearrangements have not been elucidated. Here, we used custom targeted capture and/or whole-genome sequencing to characterize oncogene rearrangements across 883 mature B-cell lymphomas including Burkitt lymphoma, follicular lymphoma, DLBCL, and HGBCL-DH-BCL2 tumors. We demonstrate that, although BCL2 rearrangement topology is consistent across entities, HGBCL-DH-BCL2 have distinct MYC rearrangement architecture relative to tumors with single MYC rearrangements or with both MYC and BCL6 rearrangements (HGBCL-DH-BCL6), including both a higher frequency of non-IG rearrangements and different architecture of MYC::IGH rearrangements. The distinct MYC rearrangement patterns in HGBCL-DH-BCL2 occur on the background of high levels of somatic hypermutation across MYC partner loci in HGBCL-DH-BCL2, creating more opportunity to form these rearrangements. Furthermore, because 1 IGH allele is already disrupted by the existing BCL2 rearrangement, the MYC rearrangement architecture in HGBCL-DH-BCL2 likely reflects selective pressure to preserve both BCL2 and B-cell receptor expression. These data provide new mechanistic explanations for the distinct patterns of MYC rearrangements observed across different lymphoma entities.

Indexed as

Gene RearrangementProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-mycHumansLymphoma, B-CellLymphoma, Large B-Cell, DiffuseBCL2 protein, humanMYC protein, humanProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-myc

Identifiers

PMID38701426
PMCPMC11307266

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.